- The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig® (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years to 140mg
- 4.5-year data show 77% of the patients who continued on treatment experienced at least a 50% reduction in monthly migraine days (MMD) at the last month of assessment
- Moreover, 33% of patients who continued on treatment achieved a 100% reduction, and 56% achieved a 75% decrease in MMD
- These additional long-term data complement Aimovig’s position as the most prescribed anti-CGRP, with more than 250,000 patients prescribed worldwide since launch
Basel, September 09, 2019 – “We are pleased to see that during the OLTP, Aimovig® was not only able to reduce monthly migraine days, but also decrease the number of days requiring acute migraine-specific medication” said Estelle Vester-Blokland, Global Head Neuroscience Medical Affairs, Novartis Pharmaceuticals. “These 4.5-year data further add to Aimovig’s established benefit for people living with migraine. Novartis is committed to reimagining migraine care, by providing patients with an effective preventive treatment option so that they may take their lives back from this highly debilitating disease.”
About the Open-Label Treatment Period (OLTP) in Episodic Migraine
This is a 4.5-year, interim analysis of a 5-year, open-label treatment period (OLTP) in patients with episodic migraine (NCT01952574) to evaluate the sustained efficacy and long-term safety of Aimovig in patients taking 70mg and 140mg. In the OLTP, patients initially received 70mg of Aimovig monthly. The dose was increased to 140mg for the patients continuing the study after ~2 years. Of the 250 patients who switched from Aimovig 70mg to 140mg, 221 patients (88%) completed the OLTP or remained on 140mg at 4.5 years. From a baseline of 8.7 [2.7] and 6.1 [2.7] days, a change of - 5.8 [3.8] and - 4.6 [3.3] was observed for monthly migraine days and acute migraine-specific medication treatment days respectively. Efficacy endpoints for the OLTP included change in monthly migraine days and change in acute migraine-specific medication treatment days from baseline. The safety analysis was performed by evaluating the exposure-adjusted incidence rate of adverse events data of the 12-week short-term studies and the OLTP of up to 4.5 years. No new safety signals were observed for Aimovig, whose safety profile and tolerability were in line with previous clinical trial data.
About Aimovig (erenumab)
Aimovig is the first EMA, Swissmedic, Australian TGA and FDA-approved migraine prevention treatment designed specifically to block the calcitonin gene related peptide receptor (CGRP-R), which plays a critical role in migraine. Aimovig has been studied in several large, global, randomized, double-blind, placebo-controlled studies to assess its safety and efficacy in migraine prevention. More than 3,000 patients have participated in our overall clinical trial program. This includes 2,600 participants across the four placebo-controlled pivotal Phase II and Phase III clinical studies as well as participants in further studies such as LIBERTY, a dedicated study in a difficult-to-treat treatment failure population. The most common side effects in the clinical program to date have been viral upper respiratory tract infection, upper respiratory tract infection, sinusitis, influenza, and back pain.
Novartis and Amgen are co-commercializing Aimovig in the US. Amgen has exclusive commercialization rights to the drug in Japan and Novartis has exclusive rights to commercialize in the rest of the world.
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products or the collaboration with Amgen. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that the collaboration with Amgen will achieve any or all of its intended goals, or within any particular time frame. Nor can there be any guarantee that such products or the collaboration with Amgen will be commercially successful in the future. In particular, our expectations regarding such products and the collaboration with Amgen could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis or follow @NovartisNews for the latest media releases and updates at https://twitter.com/novartisnews
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact [email protected]
 Messoud A, et al. Sustained efficacy and long-term safety of erenumab in patients with episodic migraine: 4+ year results of a 5-year. IHC 2019.
# # #
Novartis Global External Communications
E-mail: [email protected]
| Antonio Ligi|
Novartis Global External Communications
+41 61 324 1374 (direct)
Novartis US External Communications
+1 646 438 4335 (direct)
| Rachel Fink|
Novartis Global Pharma Communications
+41 61 324 8245 (direct)
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 778 5052|
|Pierre-Michel Bringer||+41 61 324 1065||Cory Twining||+1 862 778 3258|
|Thomas Hungerbuehler||+41 61 324 8425|
|Isabella Zinck||+41 61 324 7188|| |